NCT02999763已完成不适用
Clinical Study to Evaluate the Safety and Efficacy of the SlimShape Device for Abdominal Fat and Circumference Reduction
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 6
- 主要终点
- Change in Fat Thickness at Final Follow-up Compared to Baseline
研究概览
简要总结
Prospective, one-arm, baseline-controlled, clinical study for the evaluation of the SlimShape device for non-invasive abdominal fat and circumference reduction.
Study subjects will undergo SlimShape treatments on the abdominal area.
详细描述
The objective of this trial is to evaluate the safety and efficacy of the SlimShape device utilizing the SlimShape Applicator Belt for abdominal non-invasive fat and circumference reduction. Eligible subjects will receive up to 3 bi-weekly treatments (2 weeks interval) with the SlimShape device utilizing the SlimShape Applicator Belt according to the study protocol.
The subject will return for 3 follow up visits: four weeks (4wk FU), eight weeks (8wk FU) and 12 weeks (12wk FU) after the last treatment.
Each subject will be enrolled for total expected study duration of up to 16 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Signed informed consent to participate in the study.
- •Female and male subjects, ≥18 and ≤60 years of age at the time of enrollment
- •Fitzpatrick Skin Type I to VI
- •BMI interval: 18.5 ≤ BMI ≤ 30 (normal to overweight, but not obese).
- •If female, not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
- •In addition, negative urine pregnancy test as tested before each treatment and at the last visit for women with childbearing potential (e.g. not menopause).
- •General good health confirmed by medical history and skin examination of the treated area.
- •Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
- •Willing to refrain from a change in diet/ exercise/medication regimen for the entire course of the study.
- •Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.
排除标准
- •History of hypertension, ischemic heart disease, valvular heart disease, congestive heart failure, pacemaker/defibrillator, abdominal aortic aneurism
- •Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue disease
- •Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including presence of malignant or pre-malignant pigmented lesions
- •Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator
- •Having a permanent implant in the treated area, such as metal plates or an injected chemical substance such as silicone
- •Having undergone any other surgery in the treated areas within 12 months of treatment or during the study, including liposuction
- •Previous body contouring procedures in the treatment area within 12 months
- •History of skin disease in the treatment area, known tendency to form keloids or poor wound healing
- •History of epidermal or dermal disorders (particularly if involving collagen or microvascularity)
- •Suffering from significant skin conditions in the treated areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course
- •Allergy to any component of the lotion (VelaSpray Ease) used in this study
- •Skin lesions in the treatment area other than simple nevi on physical examination (e.g., atypical nevus, tattoo, abrasions) including depressed scars in the treatment area
- •Very poor skin quality (i.e., severe laxity)
- •Abdominal wall diastasis or hernia on physical examination
- •Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood count within the last 3 months
- •Obesity (BMI > 30)
- •Childbirth within the last 12 months or breastfeeding women. Any acute or chronic condition which, in the opinion of the investigator, could interfere with the conduct of the study
- •Unstable weight within the last 6 months (i.e., ± 3% weight change in the prior six months)
- •Inability to comply with circumference measurement procedure (e.g., inability to hold breath for the required duration).
- •Participation in another clinical study involving same anatomical areas within the last 6 months (or 30 days in case different anatomical areas were treated in previous trial/s).
- •As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
研究组 & 干预措施
Abdominal fat reduction treatment
Experimental
SlimShape treatments will be administered for up to 3 sessions to the abdomen of all study participants.
干预措施: SlimShape (Device)
结局指标
主要结局
Change in Fat Thickness at Final Follow-up Compared to Baseline
时间窗: Baseline and 12 weeks follow-up
Abdominal fat change, measured by ultrasound, post SlimShape treatments at 12 weeks follow-up (12wk FU) compared to baseline
次要结局
- Change in Fat Thickness After Treatments Compared to Baseline(Baseline and 4 and 8 weeks follow-up)
- Change in Abdominal Circumference After Treatments Compared to Baseline(At 4 weeks, 8 weeks and 12 weeks follow-up (post last treatment))
研究者
研究点 (6)
Loading locations...
相似试验
已完成
不适用
UltraShape Power for Abdominal Fat and Circumference ReductionExcess Abdominal FatNCT02748928Syneron Medical62
已完成
不适用
Efficacy and Safety of the BeShape One Device for Non-invasive Waist Circumference ReductionDermatological Non-DiseaseNCT05896696BeShape Technologies Ltd.81
已完成
2 期
Cohera TissuGlu® Surgical Adhesive in the Management of Wound DrainageAbdominoplastyNCT01526954Cohera Medical, Inc.150
Unknown
不适用
Non-Invasive Abdominal Fat Reduction With BMI Above 28Unwanted FatNCT02711618Syneron Medical47
Unknown
2 期
The Safety and Efficacy of the Combination of Raltitrexed for Injection and Nab-Paclitaxel in Advanced Pancreatic CancerChemotherapy EffectPancreatic CancerNCT04581876Fudan University120